
Genda-Bio develops peptide-based nucleic acid delivery products for primary cells and other hard-to-transfect cell types. Its GentleFect platform uses a non-viral and non-lipid delivery approach designed for applications where conventional chemical transfection may provide low efficiency or poor cell viability.
The portfolio covers research-grade transfection reagents, cell therapy process-development products, messenger RNA, circular RNA, custom nucleic acid services and basic cell culture media.
GentleFect uses engineered peptides that self-assemble with nucleic acids to form delivery complexes. The platform is designed to introduce nucleic acid cargo into primary cells while preserving cell viability.
Supported nucleic acid formats include:
The workflow does not require an electroporation instrument, making it potentially useful for laboratories seeking a chemical transfection method for primary cells.
Performance still depends on the target cell, nucleic acid quality, cargo size, cell density and culture conditions.
Gentle T30 is developed for nucleic acid delivery into primary T cells.
Applications include:
The product is available in several package sizes, allowing researchers to move from initial testing to larger experimental workflows.
Cell activation status can influence transfection performance. Researchers should evaluate transfection efficiency together with cell viability, expansion capacity and phenotype.
Gentle NK30 is designed for primary NK cells, which are often difficult to transfect with standard lipid-based reagents.
Potential applications include:
Because NK cells can be sensitive to both transfection and handling, post-transfection viability and cytotoxic function should be assessed alongside delivery efficiency.
The GentleFect product family also includes:
Reagent selection should be based on the exact cell population. A general primary-cell reagent may not perform identically to a product optimized for T cells, NK cells or stem cells.
Genda-Bio supplies ready-to-use nucleic acid products and custom synthesis services.
Available products include:
Reporter mRNA can be used as a positive control when establishing a new delivery protocol before testing a more complex experimental construct.
The Genda-Bio catalog also includes high-glucose DMEM, low-glucose DMEM and sterile PBS for routine cell culture workflows.
These products complement the company’s transfection portfolio but should be selected according to the requirements of the target cell and experiment.
Genda-Bio products can support:
Biolterna can assist with sourcing Gentle T30 Transfection Reagent for Primary T Cells, Gentle NK30 Transfection Reagent for Primary NK Cells and other GentleFect products.
When requesting a suitable reagent, provide the cell type, nucleic acid format, approximate cargo size, culture conditions and required experimental scale.
Research-grade and process-development products should be distinguished from materials manufactured for regulated cell therapy workflows.
Official website link: